On November 17, 2022, LifeSci Special Opportunities Master Fund Ltd. announced that it issued a statement in response to Diffusion Pharmaceuticals Inc's misleading press release from November 14, 2022 and announced that it has nominated a slate of quality director candidates; Jill Davidson, Tenzin Khangsar, Jeffrey Kimbell, Jessica M. Lockett, Jeffrey Max, John Ziegler for election at the Company's upcoming annual meeting to be held on December 30, 2022. In addition, LifeSci Special stated that it intends to file a preliminary proxy statement and accompanying universal proxy card with the Securities and Exchange Commission to be used to solicit votes in connection with the 2022 annual meeting of stockholders of the Company.